Latest Heparin Stories
PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has clearance to start human clinical trials in the United States with its anticoagulant reversing agent PMX-60056 under the Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents an entirely new class of drug, which...
PolyMedix Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a registered offering in which it raised a total of $15 million in gross proceeds from the sale of common stock units. The units were priced at $0.70 per unit which at closing separated into a share of PolyMedix common stock and a five year warrant to purchase a share...
U.S. health officials say they have been able to connect three deaths to a contaminated batch of the blood-thinning drug heparin. A spike in the number of allergic reactions by hospital patients injected with the drug prompted its manufacturer, Baxter International Inc., of suburban Chicago, to pull the heparin from distribution in February. Since then, the U.S. Food and Drug Administration has been examining reports of 93 deaths related to heparin. An FDA scientist told the Chicago Tribune...
CAMBRIDGE, Mass., July 29, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today will present safety and tolerability results from a Phase I study of M118, its rationally engineered anticoagulant, in a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics Meeting. The poster, titled "Safety, Tolerability, Pharmacokinetics and...
By CHRISTOPHER SHERMAN, THE ASSOCIATED PRESS CORPUS CHRISTI, Texas The case of 14 babies who received accidental overdoses while in intensive care has raised new questions about how a common blood-thinning medication could be given to infants repeatedly in the wrong dosage. Unlike a previous case involving Dennis Quaid's twins, the Texas newborns got the overdose because of an error at the hospital pharmacy, not a labeling problem. The actor sued one of heparin's manufacturers last year...
By The Associated Press CORPUS CHRISTI, Texas (AP) - The case of 14 babies who received accidental overdoses while in intensive care has raised new questions about how a common blood-thinning medication could be given to infants repeatedly in the wrong dosage.Unlike a previous case involving twins of actor Dennis Quaid, the Texas newborns got the overdose because of an error at the hospital pharmacy, not a labeling problem.Quaid sued one of heparin's manufacturers last year after his...
As many as 17 infants, including one who died, may have received overdoses of a blood-thinning drug at a Texas hospital. The error occurred at Christus Spohn Hospital South in Corpus Christi, Texas. Richard Davis, chief medical officer for the Christus Spohn Health System, said doctors don't know if the overdose of heparin played a role in the death, since the baby was already very sick, the Corpus Christi Caller-Times reported. Nurses discovered Sunday night that some infants' blood wasn't...
ALBANY, N.Y., June 26 /PRNewswire/ -- Shaker A. Mousa, Ph.D., executive vice president and chairman of the Pharmaceutical Research Institute (PRI) at Albany College of Pharmacy (ACP), has been awarded a $368,445 research grant from the National Cancer Institute, part of the National Institutes of Health. Dr. Mousa along with a team of PRI investigators that includes Dr. Lawrence Lansing, Dr. Lakshman Sehgal, Dr. Murat Yalcin and PRI technical staff, will study new methods for limiting the...
Trinity Biotech plc (NASDAQ: TRIB) is pleased to announce that it has been appointed by Akers Biosciences, Inc (LSE: AKR) ('ABI'), a leading designer and manufacturer of rapid diagnostic screening and testing products, as a distributor of its unique PIFA Heparin/Platelet Factor-4 Rapid Assay (HPF4) in the USA and German markets. Heparin is the most widely used intravenous anticoagulant, and is commonly used for the prophylaxis and treatment of thromboembolic disease. It also has numerous...
NORTHBROOK, Ill., June 24 /PRNewswire/ -- New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies. Published as a supplement in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and Thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an...
